AC Immune (ACIU) COO Piergiorgio Donati reports shares and long-dated options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
AC Immune SA Chief Operating Officer Piergiorgio Donati filed an initial ownership report detailing his equity position. He directly holds 141,120 common shares, which include 136,620 common shares underlying outstanding restricted share units. In addition, he reports multiple share options over common shares with exercise prices between $2.03 and $9.50 per share and expiration dates from July 2028 through December 2035. Some options are already fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026, providing a staggered schedule of potential future share deliveries.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Donati Piergiorgio
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 7,200 shares (Direct);
Common Shares — 141,120 shares (Direct)
Footnotes (1)
- Includes 136,620 common shares underlying outstanding restricted share units. The share option is fully vested. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2024. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2025. The share option will vest in twelve substantially equal quarterly installments beginning on March 31, 2026.
FAQ
What does the AC Immune (ACIU) Form 3 filing by Piergiorgio Donati show?
The Form 3 shows Chief Operating Officer Piergiorgio Donati’s existing equity stake in AC Immune SA, including common shares and multiple option awards, establishing his baseline ownership as an insider for future SEC reporting purposes.
Are any of Piergiorgio Donati’s AC Immune (ACIU) options already vested?
Yes. A footnote states that at least one share option is fully vested. Other option grants will vest in twelve substantially equal quarterly installments, providing gradual vesting over time rather than all at once.
When do Piergiorgio Donati’s AC Immune (ACIU) options begin vesting?
Certain options begin vesting in twelve substantially equal quarterly installments starting on March 31, 2024, with others beginning on March 31, 2025 and March 31, 2026. This creates staggered vesting schedules across multiple award years.
Does the AC Immune (ACIU) Form 3 show any recent buying or selling by Piergiorgio Donati?
The data presented reflect holdings rather than new purchases or sales. Transactions are characterized as holding entries with unknown transaction codes, so the filing mainly establishes Donati’s current equity position, not recent trading activity.